Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Powerwalker, please re read 41 week announcement.
at 41 weeks A2-73 provided Regression Free Survival as no
other medication ever has..SOC..and with positive side effects..
we should have access..oh well..
we have been beat down by Short n Distort and lack of Media/AD Organizational help..It's hard to come out of that bunker and be a
BBBBeliever!
MJFF, Biogen(MS Test Result?),Rett Syndrome, Other IND's!, Cogstate, Neuronetrix, Ariana, New Parkinsons Annoncement Phase 2/3 (MJFF) experts join the Board, Pain Medication's(non-addictive) Success in Vivo testing,
New mentions from the good Dr:
1. Data from Mono Therapy so convincing as to DROP Dual Therapy as target of continued study. How good must Data be for MonoTherapy to convince the Scientific Board and the good Dr to DROP Dual Therapy data as a target?
2. Dual Therapy no longer Target as dual Therapy shows no additional benefit to MonoTherapy. MonoTherapy Data so good shows first ever 41 week REGRESSIVE FREE SURVIVAL and confirmed planning for Phase 2/3 in AD.
3. May be faster way to approval.and new target confirmation at.end of 41 week announce..
“This data provides valuable safety, tolerability and behavioral information for ANAVEX 2-73, which might allow us to also target shorter-term endpoints including behavioral and psychological symptoms.”
man if only we could read..and english is not the good Dr.'s first language.
BBBBBBBBBillions..who the heck is giving away their assets for $.10 on the dollar? give Corey a call over at the Fool, he has a great place to invest your money..
So this will be my last message of day..but you guys still don't get the significance of dropping Dual Therapy Target..
WHAT DID THE good Dr SEE to MAKE HIM DO THAT? He told you 9 MONTH was Rock Steady-Unbelievable
..WE HAVE THE DRUG!
Funding will be cheap and plentiful and from wherever the good Dr. wants to get it! again..WE HAVE THE DRUG..LET THAT SINK IN..
The Value of Azheimer's alone took the Market Value of
Biogen up $30 BILLION in 3 months! Lilly went down $8 BILLION in Market Value in one day with it's failure in Alzheimers.
We have a drug with Positive Indications for Alzheimers(between or more that 8 and 30 BILLION short term), Parkinsons( Is it any less?)
Positive Side Benefits, potential for expanding IND in CNS and general heatlh..
Really guys and gals walking away with less than $50 BILLION is ridiculous..
and WHO says we are walking away?
Why would we be adding Board Members if we were folding into another entity?.......
You got that right.
Retail is worried about trading $.1
Institutional moves in Billions..
thank you, glad someone appreciates my sense of humor!
I am on day 4 of CBD/Vicks..
feeling GREAT!
haha
and in a Perry Mason Moment: Good Timing on the good Dr's part ..hunh
https://www.congress.gov/bill/114th-congress/house-bill/6
http://www.modernhealthcare.com/article/20161127/NEWS/161129944
did I mention ..the Sigma 1 Lignad plays an important role in
Opioid abuse?
froll..so .. Basketball is a really quick game..and one or two points makes all the difference , especially at the end..
so when you as a team are losing..you are fouling, pressing the ball..trying everything you can to make something happen..you are in a frenzied state! but the SECOND you get the Lead..the SECOND...
Everything changes..slow the tempo..make a good pass,,don't foul..
Even with a scoreboard it's hard to ACT in the moment much less realize what has occurred..to change..to recognize the change..
I think you really have to look at the scoreboard because I think the game has changed..
The Market makers look like they are balancing buys and sells..
limited pre-market price run ups to get shorted(buyers maybe a little smarter)..but I think the Market Makers are doing their job now..
Either they are part of a new game..or a big dog has entered the room..
Also note the lack of Fear Mongering Short Distorters on the Board?
the lack of negative articles in the Street, Ship of FOOLS..
I think the scoreboard says ..Longs have the lead..steady on..Accumulate!
wow..I would take a share of Biogen for a share of Anavex..
right now..and I think that would be fair!
Courtesy of previous post of Amateur17
Xena
Did you watch the Maurice Lecture?
That lecture combined with the past notes from others really is an eye opener.
We have a tag team of cellular repair working in unison.. for homeostasis..
It's beautiful.
Ziggy..how do we skip phase 2? By moving into the 21st Century .
The Phased studies of a drug were designed well before the Internet and Super Computing were invented much less possible. We now may manipulate trillions of databytes from current Testing(Safety and Efficacy), past Studies and Patients, and even have computer modeling of the human body.
the entire Phase studies program needs to be reviewed for Efficacy and efficiency. having said all that..
Ariana was explicity brought on board to extricate data for Alzheimers, Parkinsons and Rett Syndrom..maybe more..
We have Safety in Humans confirmed.and IMO Efficacy as well.
Phase 1/2..
now we need Efficacy and continued safety and best dosage.. Phase 2/3..
SO why wouldn't Parkinsons do a Phase 2/3 with early test points for Efficacy and Dosage? There might be a different Maximum Effective Dosage for Parkinsons than Alzheimers, but maybe not..
But here is the other point of WHY Parkinsons may be first IND for
A2-73, the relief of Visible Signs of Parkinsons may allow for early Humanitarian Approval. Thus allowing for Access..(basically skipping Phase 2..) All my humble opinion..
Ariana's addition and mission is brilliant.
Not worried about "loot"..
Just want availability as quckly as possible..
Alzheimer's decline is mostly cognitive over time..this is harder to measure and observe than physical corrections..
In animal studies, time after time, the administration of A2-73 provides relief, almost immediate to the animal..
It will make the benefits of A2-73 more immediately noticeable in Parkinsons sufferers..and that is good for humanitarian availability for everyone.
I don't know about 90% but I do know that many Institutional buyers are both restricted by Share Price ($5 is a point), market Cap and ongoing revenue.
The buyers we are looking for are probably only limited by Share Price.
It is written in the covenants..
But now I think there are plenty of institutions capable of buying below $5.. I would think Margin .. would be a big dong at $5..
bio..IMO ..this is confirmation of Phase 3 in Parkinsons with MJFF involvement/funding.
the problem all these IND partners are going to have and somewhat Anavex,
cross prescriptions..
First approved Indication. wins..
After listening to awesome Dr Maurice lecture..
3 things.. our sigma 1 agonist does not target any specific Sigma 1 ligand.
To me this is a Lightning Bolt..
Why there are no Ill Side Effects and there are Positive Side Effects..
I knew the Sigma 1 are located in the CNS but also knew the heart , the eyes..
the Dr mentioned the Liver and the Lungs..
Wow..and A3-71 is supposed to be bigger and stronger? Super man!
Amateur.
The good Dr mentioned in an interview with Wall Street Week( I think) that Dual therapy showed no benefit..or something like that..it was phrased strangely..but basically ..that Dual Therapy showed no additional benefit to Mono therapy ..and I forget how he said it..but basically said, dual therapy was no longer a target ..it was unbelievable!
But if you go back to 6 month Data..the good Dr tried to use non declarative wordings in describing the DataSets of Mono vs Dual vx Averaged..
There is no need to ask the good Dr anything as on Dec 8th we get our answers..
Really at this point..the good Dr. has to be considered one of the geniuses of BioPharma and second hand guessing by all of us, really is silly.
The good Dr knows what he is doing and he owns shares just like us..
I laugh at the people who said he needed "a Lab" or he should have gone all dilutional at 5 weeks data..or ..or..or WHAT?
He has enough money to get us to Dec 8th..that is for sure..
After that..If the study has gone all MONO and the ne MONO people are responding like the original 7..governments will THROW MONEY at Anavex..
i think they tried..and they have destroyed price for 2 years..
we were at $14..i think the dogs have been called off..
whoever it was ..doesn't need them anymore ..for whatever reason..
that would be a good wkkileaks...
Anavex has access to all the financing they will ever need..
Cheap..
So.. I just sense a difference in trading patterns. It's almost as if the enemy has quietly left their bunkers in the middle of the night and the acrid smell of sulfur powder has drifted onward. The only way that happens is if the dogs were called off, either to set a higher price for short and distort or.. most likely their masters have accomplished their goal.
IMO that would be AXON has reached CTAD without being dominated by Anavex or Biogen has come to terms with Anavex .. just speculation..
The Market Makers are trading with the orders.. no momentum sucking up drifts and drip downs..they just look like they should have looked All along.. balanced.. it appears someone has callled off the FOOLS..they own Biogen stock for whatever that's worth..wonder if Corey Renauer still employed?
The not statistically different was couched in protective caveats..
Obviously mono therapy performed better..
Ok. Blu_. You are a little behind..
The good Dr has mixed Dual Therapy as having no benefit over mono therapy , aka, mono therapy works better..
The good Dr stated the change in an interview..but there is no mention of Dual Therapy at 41 weeks..
You should always reserve the right tbuy or sell as circumstances change..
I am trying to figure out how to buy more next week..
About 3/4 of way through he talks about "effecting and modulating" .
It's a great presentation.
I agree!
Remember Anavex sees Mono Therapy results out for some patients cloae to two years!
IF and it's a big if, dual therapy patients dropped Aricept/Donezipil and just went A2-73 Mono and IF those patients charted like Mono Therapy Patients charted in MMSE at 3 months..
I mean. Wow.. And that is the type of Data I think the good Dr had to see to just Drop Dual Therapy like a cold stone..
I believe it was Street Interview,
No mention of Donezipil or Dual in 41 week release..
" preliminary" "unequal sample size" "stratification" "exploratory analysis"
Like I said.. what Data must the good Dr have received ( guessing Ariana partnership paying dividends) to so quickly throw in the towel on Dual Therapy? IMO it was not that dual therapy was ineffective or not even that Dual Therapy Data was good enough for Phase 3 or new SOC..
No.. what hit the good Dr upside the head.. was confirmation of that
Mono MMSE graph that moved up
10% 3 months into an Alzheimer Phase 2a..
Missing did my state there was no difference .. they hedged their wording saying the data was averaged in different Strata .
You can read the wording underneath the charts at 6 months..
Two things
The good Dr minced words at 6 months because he had to..
The data showed success when averaged but he could not confirm it was the Mono Therapy line. Not enough Data. Subsequent the good Dr has confirmed "dual therapy" not the reason for the Phase 3.
Hence 12 month Data must be a continuation of the Monotherapy line..
If this were a Cancer Trial progression free survival of 30% of Patients would be a home run at 6 months..
We have a home run..
So, great question and it's a question of logic ,so I am not the greatest communicator so try to stay with me..
This is an open trial, there are no Blinds, no placebo, patient information is immediately available to Doctors . So at 6 moth report many patients were already past 12 months..so even though the good Dr could only show us 6 month non confirmatory data, he saw 12 month mono therapy and knew. Hence Why he put Mono Therapy data charts in..
Otherwise why bother?
The simple logic is :
The Data showed effectiveness at Stopping deterioration, but it was ONLY when you averaged the MoNo data in with the dual therapy data..
So. The DATA was good enough to Actuate a Phase 3! The shorts were following the average of dual and knew Alzheimer would take that average down even more.
What is making the shorts run is MY logic. The Dual Data is meaningless! The only Data or Effect that matters is Mono Therapy .. go look at those Mono Therapy charts..
But how does the adaptive trial confirm only 7 Patients .. it must be 100% Effect for all Mono Patients
AND I think they had patients opt from dual therapy to Monotherapy thus giving him confirmatory data that the positive results of this population AND the original 7 mono therapy patients provided enough confirmatory data to proclaim Dual Therapy no longer a target.( patent issues may have pushed this decision as well). But remember The good Dr said this could only be determined in a larger trial.. What Changed? The Positive Data from Mono Therapy changed .. THAT is the Data that matters.. review the data you have for
Mono Therapy.. we saw it at 6 months..
No Alzheimer Chart goes UP at 3 months.. no Placebo ,, no nothing.. after 3 months it's get out your reversible ratio regressive measures.
No One measures how far UP you went at 3 Months! Never Have!
That's it JonJonea.. when the good Dr said no to Dual Therapy he confirmed the Mono Therapy Data.. BAM!
Biogen needs Anavex more than Anavex needs Biogen..
I always felt some of the attack sycophants had some relationship with Biogen.. or Axovant .. or both.
Maybe to make negotiations go easier..
They were fools who had a long relationship with. Up gen who were relentless on their Anavex assault..
Doesn't Biogen have a drug that affects Plaque? Just not Alzheimers...
As I said earlier , first you must stop the cascade of inflammation.. maybe you may attack the plaque during this process..
Nicely written. In retrospect, it's nice to dissect developments "pre mono-therapy confirmation" now that we know. IMO we know that that the MMSE chart from 3 month to 6 month was confirmatory of "SOC" and I believe Biogen would have had access to that data. So Biogen figured out a way to get its foot in the door by throwing MS at Anavex.. Brilliant move on Biogens part! The good Dr would not have turned away the opportunity to help other sufferers quicker.
What do you think the reaction inside Biogen was when they saw the MonoTherapy Data from 2 years back for A2-73 Patients?
Do you think they are going to wait until after Dec 8th to make an offer?
Would you?
Also to be clear,
I don't recommend anyone selling ever. Use this stock as collateral for generational wealth!
You can not pay too much for this stock.
As the frustration and failures pile to the ceiling of
those who have tried to stop Alzheimers,
as the acrid smoke of Capital's burning fire fills the room,
The cries of those whose hopes have turned to ash, escape to be heard,
"God Bless You all for trying, please do not stop".
Investors in Anavex, heard this call, and into this
room of failure, destruction and death they walked. Hopeful.
They poured tens of millions of dollars of precious capital
into a drug that was different. The Drug, A2-73, (a non-opioid) activated the Sigma 1 Ligand, a type of stimulation that had been tried before many times to some effect for different maladies.
The difference, was ..Anavex had a better Agonist (like we hadn't heard that before) and they combined it with a Muscarinic?
In laymen's terms, one to light the fire and the other to control it?
Fire and Ice? We are going to PULL the Body's Fire Alarm
to call out the Paramedics(Sigma 1 Agonist) and the Firemen(Muscarinic) will calm everything around to keep the Paramedic focused.
It is a brilliant combination. But really who knew?
Trillions have poured over the Night's endless river of failure at treating Alzheimers and some of the real heroes must be the Investors
who first funded Anavex.
A hearty call out to Maxim Group and their Clients!
Thank You!
The PROBLEM with almost ALL the other drugs is very simple.
They did not work. You could tell they did not work, Prima Facia. Companies paid billions to prove that
"You could put lipstick on a pig".
Now the intelligentsia, the lipstick salesmen, form a circular firing squad, and cry out for more, "12th Century Medicine".
Use more people in a Trial! Don't Substrate your Groups into those who
got better!
The Intelligentsia grows weary of risk takers losing money on hope!
There is hope, as many of their drugs do have effect, but they are not stopping the root cause, the Cascading Inflammation of CNS cells.
The inflammation caused by multiple variant issues must be slowed, stopped and then brought into an operational HOMEOSTASIS.
No single drug may accomplish this task, as at some point, the body reacts to the Agents themselves, as cause for Inflammation.
Therefor, any effect at treating the "evidence" of Alzheimers are pointless, until you stop the cascade of inflammation.
Even Anavex A2-73 may not do all this, BUT our body has a Chaperone, and THAT Chaperone CAN and DOES do HOMEOSTASIS. A2-73, by calmly agonizing the Sigma One Ligand, effectively slows and stops the cascading inflammation of CNS distress. Don't throw these other drugs away, as once you have stopped the "bleeding", the cascading, ALL these other drugs may work. A2-73 by slowing or even stopping the cascade of inflammation, may allow for the successful treatment of Moderate to Severe Alzheimer's with these other drugs. Don't listen to the cry baby Intelligentsia that cheered your efforts with your Trillions of dollars and then jeered your Failures. Now that they grow weary, success is at hand.
It's just not what the Intelligentsia foresaw. It's not the"RIGHT" people. So the Intelligentsia ignore Anavex. They loose their pet sycophants upon them. The good Dr, Anevex's Shareholders and believers are unbowed!
Use the tools that early medicine never had, like what Ariana Pharma is doing for Anavex. Absolutely manipulate the data of past failure and current success a million times faster than ever conceived to lighten your load and find the quickest path. Adaptive Trials like Anavex's Phase 2a, designed with FDA help and guidance. are the way of the future. Use them as Anavex did, to try and make your Drug FAIL, and by logic, IF your Drug does not fail,
than it must beautifully succeed!
The good Dr.has a very important date December 10th,
and I assure you, she doesn't need any lipstick.
The sellers have been coordinated short attacks and market makers shorting pre market tops to demoralize buyers. Market Makers have been acting normal( books in balance) and the parade of the soulless has been minimal..
Now. The sneaky sons of guns could be up around next bend.. but they also may be able to read
Biogen and see 6 month MMSE chart for Mono Therapy..
there were 6 million shares sold short..
Doubt if many covered..
All longs have to do is not sell..
Put trade shares at offer over $ 5. And we are gone..
Buy volume needed,,but again.
Who is selling?
We have the drug..
Oh well
This was probably Biogen announcement w/heavy buy volume
That could not be sustained.
IMO most Biogen buyers averaged down and will go green through
$4.50.
The risk to reward scenario has improved with MonoTherapy confirmation.
The market place for replacing Donezipil, Aricept , Mementine
And patients who could not stomach at of their side effects is Billions.
It appears AXON is the closest
"Competition " to ours but we already know their drug is being studied as combo(pretty sure) and is being measured by how much it SLOWS deterioration ,, not STOPPING.
Honestly,
The second the good Dr confirmed the Mono Therapy data we saw at 6 months Anavex should have been through its all time high of $14.
Scared of what? Dec8? Think not.
Why are stakeholders accepting less than $5 a share? IMO Over $5 is coming next week. .. just sell your trading shares at offer price over $5!
This will let risk takers and believers leverage up.. before Dec8..
MMSE normally drops 3-4 points per year,, mono therapy started at 21.5 less - 3.5 looking at ficticeous Blind Placebo group at 18 at one year.
At 6 months our MMSE for Mono was around 24.5. With positive side effects (again reiterated by the good Dr) and really estimate at worse a 2.5 drop from 6 months..22. We are still above our start point of 21.5. After 1 year!
It's very exciting..
the market value for a succesful Alzheimer Drug is over $8,000,000,000..
period.
the anavex market value is $130,000,000. 50 times?
shortus delerium dilutorum .there will be NO PROBLEMS raising $$ at
very favorable rates for Phase 2/3..but it will be through BP probably Biogen..so who cares..Look at the risk reward?
We know so much more that one year ago..
Monotherapy..Biogen can add to some of ther developemnet drugs for answers to Patentia Extensia deletorium
My chart says we shoot through $6.5 test $8 before Dec 8th..
hang somewhere north of $5..and then come Dec.12..
we just go North for the Winter..
My fortune Telling has as much right to be on this Board as anyones..
The Media Storm for the First EVER TREATMENT that STOPS Alzheimers will
not be a One Day WOnder..but a cascade of Demand..for Public Access to
A2-73...The Value of Anavex will help them provide A2-73 to markets faster.. We fight the good fight..Go Anavex Go!
dry17 what a brilliant post!
A #1 on Zach's! WOW! how the worm has turned.
Why it seems like just last week the Motley Fool was begging everyone to sell, sell, sell and buy one of their GUARANTEED TOP TEN PICKS!
How do we explain these two statements:
at end of 6 months:
." Likewise, when tentatively stratified between ANAVEX 2-73
alone and ANAVEX 2-73 PLUS donepezil administration, no significant
difference was observed within the MMSE or the ADCS-ADL (PART B)
score, respectively. Given the small sample size, this trend would
require confirmation in a larger study. "
To: and I paranphrase to save myself time:
"We see no benefit from Dual Therapy with Donezipil"
SO..WHAT happened since 6 month Data release to around 2 weeks ago..
that took "require confirmation in a larger study" to "no benefit with
Dual therapy"?
A. Ariana knocked out some ey epopping numbers for MonoTherapy vs Dual therapy that overwhelmed..
B. Patients switched to Mono-Therapy from Dual Therapy and their results after 2 months were astounding?
Take you pick, or pick them both..either way ..something quite amazing happened on MonoTherapy to allow the good Dr to contradict himself so quickly..Something pretty doggone amazing..